CClinicalTrials.gg
Active, not recruitingNCT05056545Updated Sep 23, 2026Results posted

Postpartum Family Planning Program in Rwanda

An interventional study of C4 Intervention in Family Planning, sponsored by Emory University. Active, not recruiting at 1 site in Rwanda. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
38,220
Allocation
Randomized
Sex
All
01

Study summary

This trial wants to address high unmet need for postpartum family planning (PPFP) in Rwanda. A previous pilot study tested the intervention (informed by formative work with couples/clients, clinic providers, champions, and community health workers), which significantly increased the use of PPFP in government clinics. This study now proposes to use an implementation science framework to test the hypothesis that the proposed PPFP intervention is adaptable to large-scale implementation, cost-effective, and sustainable. This PPFP could dramatically reduce unintended pregnancy and abortion and improve birth spacing and maternal and newborn health.

Read the detailed description

In 2017-2018, the study team worked closely with the Rwanda Ministry of Health (MOH) to develop and pilot test a theory-based, multi-level intervention targeting postpartum family planning (PPFP) supply and demand in 4 government health facilities in Kigali, the capital. This innovative PPFP intervention was informed by clients, clinic providers, champions, and Community Health Workers. Long-acting reversible contraceptives (LARC), the intrauterine device (PPIUD) and implant, are fundamental to PPFP programs. LARCs are highly effective and are the only reversible methods that may be safely used in early postpartum period by breastfeeding women. During the pilot, LARC uptake among postpartum women increased significantly (172% for PP implant, 2,687% for PPIUD), PPFP feasibility and acceptability were high among providers and clients, and side-effects were rare.

In this trial, the study team used an implementation science framework to evaluate the effectiveness of different PPFP demand creation strategies and test the hypothesis that our PPFP intervention is adaptable to large-scale implementation, cost-effective, and sustainable. In a Type 2 effectiveness-implementation hybrid study, the study team evaluated facility organizational readiness prior to implementing the PPFP intervention in a clinic randomized trial in 10 high-volume health facilities in Kigali, Rwanda (Aim 1). Adaptability and sustainability within government facilities is a critical aspect of the proposal, and the MOH and other local stakeholders will be engaged from the outset. The study team expected that this project would deliver PPFP counseling to over 21,000 women/couples during the project period. They also evaluated the PPFP intervention effectiveness and implementation processes using RE-AIM (Aim 2). The team hypothesized that the PPFP intervention would significantly increase the number of stakeholders engaged, PPFP providers and promoters, couples/clients receiving information about PPFP (reach), and LARC uptake (effectiveness) comparing intervention versus standard of care. It was expected that PPFP client satisfaction resulted high and side-effects, rare. The independent effectiveness of each demand creation strategy on LARC uptake was estimated. Assessment of measures of PPFP intervention adoption, implementation, and maintenance at the patient-, provider- and stakeholder-level to assess PPFP intervention sustainability was completed by the study team. Finally, this project will evaluate PPFP intervention cost-effectiveness and develop a national costed implementation plan to guide Rwandan MOH decision-making for nationwide roll-out of PPFP services (Aim 3). This trial hypothesizes that the PPFP intervention will be cost-saving relative to standard of care.

This intervention represents an important contribution to the Rwanda Family Planning 2020 goals and the MOH are enthusiastic to see our successful pilot efforts expanded to a larger number of facilities for greater and sustained impact. The new PPFP implementation model is designed to be replicable and expandable to other countries in the region which similarly have high unmet need for PPFP.

02

Conditions studied

  • Family Planning

Keywords

  • Postpartum
  • Intrauterine Device
  • Long-acting reversible contraception
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Eligible PPFP promoters will be government facility providers working in ANC,L\&D, IV and/or postpartum services at one of the study facilities.
  • Eligible PPFP providers will be government facility providers working in L\&D, and/or family planning services at one of the study facilities.
  • Eligible Happy Client promotors will be postpartum women who received promotions and selected a PPFP method.
  • Eligible nurse/midwife and CHW promotors will be women working as nurses or CHWs at one of the intervention facilities.
  • All women eligible for PPFP services in this study will be at any stage of pregnancy or up to 14 weeks postpartum, and receiving antenatal care (ANC), L\&D, IV, or postpartum services at one of the intervention or pilot facilities

Exclusion criteria

Exclusion Criteria:

  • Prisoners
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38,220 participants (actual)

Study arms

  • Experimental
    PPFP Intervention

    The study team will train government clinic staff in ANC, L\&D, IV, or postpartum services to promote and provide the PPFP intervention at the selected facilities. Community Health Workers (CHW) and 'Happy Clients' will be trained as PPFP promotional agents. Video-based PPFP promotions will be shown at the intervention facilities. If interested in PPFP, women will be referred to the facility by their CHW.

    Behavioral: C4 Intervention

  • No intervention
    Standard of Care

    Currently, no systematic PPFP training, promotional, or service delivery activities are regularly taking place at the selected facilities. The team will compare the intervention with historical records from the facilities applying intervention and compare

Interventions

  • BehavioralC4 Intervention

    C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors. The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW.

05

What researchers measure

Primary outcomes

  1. Numbers of Clinic Directors Engaged

    Number of clinic directors engaged to support implementation of the PPFP intervention. Clinic directors were engaged at the beginning and end of intervention activities in each cluster and as needed, throughout intervention implementation to facilitate study activities until study completion.

    Time frame: Through study completion, an average of 2 years

  2. Number of Nurses Trained to Promote PPFP

    The number of nurses who complete PPFP intervention session to promote PPFP use

    Time frame: After completion of a 2-day training session

  3. Number of CHWs Trained to Promote PPFP

    The number of community health workers (CHWs) who complete C4 training session to promote PPFP use

    Time frame: After completion of a 2-day training session

  4. Number of Providers Trained to Provide PPFP

    Nurses and midwives working in labor and delivery and family planning will attend a 2-day didactic training session. Providers will complete a post-training test consisting of 10 true-or-false questions. Those who do not score at least 80% on the post-training test will be offered re-training after one week.

    Time frame: After completion of a 2-day training session

  5. Number of Providers Certified to Provide PPFP

    After completing the didactic training, providers will have the opportunity to become certified, by correctly inserting 5 PPIUDs and 5 PP implants under supervision.

    Time frame: After completion of a 2-day training session

  6. Number of Promotions to Pregnant or Postpartum Women/Couples

    The number of one-on-one C4 counseling promotions received by pregnant or postpartum women/couples.

    Time frame: Beginning at the first antenatal care visit up to post-partum week 14 (up to 54 weeks)

  7. Number of PPIUD Insertions

    The number of PPIUDs provided to postpartum women after C4 counseling. PPIUDs may refer to hormonal or copper IUDs.

    Time frame: Up to postpartum week 14

  8. Percentage of Deliveries Followed by PPIUD Insertions

    This outcome reports the percentage of deliveries followed by a PPIUD insertion in postpartum women in the Standard of Care (SOC) and C4 Intervention time periods.

    Time frame: Before discharge after delivery (up to 2 days after delivery)

  9. Number of PP Implant Insertions

    The number of PP Implants provided to postpartum women after C4 counseling.

    Time frame: Up to postpartum week 14

  10. Percentage of Deliveries Followed by PP Implant Insertion

    This outcome reports the percentage of deliveries followed by a PP Implant insertion in the Standard of Care and C4 Intervention time periods.

    Time frame: Before discharge after delivery (up to 2 days after delivery)

Secondary outcomes

  1. Cost-effectiveness/Cost-utility: Couple Years Protection (CYP)

    Cost, in US dollars adjusted for the year of data analysis per CYP

    Time frame: Years 2 and 4 of the project period

  2. Cost-effectiveness/Cost-utility: Cost Per Quality Adjusted Life Years (QALY)

    Cost, in US dollars adjusted for the year of data analysis of cost per QALY saved

    Time frame: Years 2 and 4 of the project period

06

Results

Posted Sep 23, 2026

Participant flow

The study was conducted under a waiver of informed consent. Participants include women receiving services during the intervention period; these are counted in Enrollment, Baseline Characteristics, and Participant Flow. Aggregate facility-level data from pre-intervention and intervention periods are not individual participants and are not included as enrolled.

Participant flow — Overall Study
MilestoneCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Started695458553958246118992
Completed695458553958246118992
Not completed00000

Outcome measures

PrimaryNumbers of Clinic Directors Engaged

Number of clinic directors engaged to support implementation of the PPFP intervention. Clinic directors were engaged at the beginning and end of intervention activities in each cluster and as needed, throughout intervention implementation to facilitate study activities until study completion.

Time frame:
Through study completion, an average of 2 years
Reported as:
Number · clinic directors
Numbers of Clinic Directors Engaged
clinic directorsCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Numbers of Clinic Directors Engaged22334
PrimaryNumber of Nurses Trained to Promote PPFP

The number of nurses who complete PPFP intervention session to promote PPFP use

Time frame:
After completion of a 2-day training session
Reported as:
Number · Nurses
Number of Nurses Trained to Promote PPFP
NursesCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of Nurses Trained to Promote PPFP6070542089
PrimaryNumber of CHWs Trained to Promote PPFP

The number of community health workers (CHWs) who complete C4 training session to promote PPFP use

Time frame:
After completion of a 2-day training session
Reported as:
Number · CHWs
Number of CHWs Trained to Promote PPFP
CHWsCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of CHWs Trained to Promote PPFP1110302322
PrimaryNumber of Providers Trained to Provide PPFP

Nurses and midwives working in labor and delivery and family planning will attend a 2-day didactic training session. Providers will complete a post-training test consisting of 10 true-or-false questions. Those who do not score at least 80% on the post-training test will be offered re-training after one week.

Time frame:
After completion of a 2-day training session
Reported as:
Number · providers
Number of Providers Trained to Provide PPFP
providersCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of Providers Trained to Provide PPFP2021151641
PrimaryNumber of Providers Certified to Provide PPFP

After completing the didactic training, providers will have the opportunity to become certified, by correctly inserting 5 PPIUDs and 5 PP implants under supervision.

Time frame:
After completion of a 2-day training session
Reported as:
Number · providers
Number of Providers Certified to Provide PPFP
providersCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of Providers Certified to Provide PPFP151711434
PrimaryNumber of Promotions to Pregnant or Postpartum Women/Couples

The number of one-on-one C4 counseling promotions received by pregnant or postpartum women/couples.

Time frame:
Beginning at the first antenatal care visit up to post-partum week 14 (up to 54 weeks)
Reported as:
Number · promotions
Number of Promotions to Pregnant or Postpartum Women/Couples
promotionsCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of Promotions to Pregnant or Postpartum Women/Couples769570104798262920245
PrimaryNumber of PPIUD Insertions

The number of PPIUDs provided to postpartum women after C4 counseling. PPIUDs may refer to hormonal or copper IUDs.

Time frame:
Up to postpartum week 14
Reported as:
Number · PPIUD insertions
Number of PPIUD Insertions
PPIUD insertionsCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of PPIUD Insertions9435725631513074
PrimaryPercentage of Deliveries Followed by PPIUD Insertions

This outcome reports the percentage of deliveries followed by a PPIUD insertion in postpartum women in the Standard of Care (SOC) and C4 Intervention time periods.

Time frame:
Before discharge after delivery (up to 2 days after delivery)
Reported as:
Number · percentage of deliveries
Percentage of Deliveries Followed by PPIUD Insertions
percentage of deliveriesPPFP InterventionStandard of CarePilot/Training Facilities: PPFP InterventionPilot/Training Facilities: Standard of Care
Percentage of Deliveries Followed by PPIUD Insertions91113
PrimaryNumber of PP Implant Insertions

The number of PP Implants provided to postpartum women after C4 counseling.

Time frame:
Up to postpartum week 14
Reported as:
Number · PP Implant insertions
Number of PP Implant Insertions
PP Implant insertionsCluster 1Cluster 2Cluster 3Cluster 4Pilot/Training Facilities
Number of PP Implant Insertions266020667896814775
SecondaryCost-effectiveness/Cost-utility: Couple Years Protection (CYP)

Cost, in US dollars adjusted for the year of data analysis per CYP

Time frame:
Years 2 and 4 of the project period

Results for this outcome have not been posted.

SecondaryCost-effectiveness/Cost-utility: Cost Per Quality Adjusted Life Years (QALY)

Cost, in US dollars adjusted for the year of data analysis of cost per QALY saved

Time frame:
Years 2 and 4 of the project period

Results for this outcome have not been posted.

PrimaryPercentage of Deliveries Followed by PP Implant Insertion

This outcome reports the percentage of deliveries followed by a PP Implant insertion in the Standard of Care and C4 Intervention time periods.

Time frame:
Before discharge after delivery (up to 2 days after delivery)
Reported as:
Number · percentage of deliveries
Percentage of Deliveries Followed by PP Implant Insertion
percentage of deliveriesPPFP InterventionStandard of CarePilot/Training Facilities: PPFP InterventionPilot/Training Facilities: Standard of Care
Percentage of Deliveries Followed by PP Implant Insertion38311711

Adverse events

Collected over Through the end of study follow-up, up to post-partum week 14 (total up to 54 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PPFP Intervention1/16,254 (0%)2/16,254 (0%)25/16,254 (0.2%)
Most frequent serious events
Most frequent serious events
EventPPFP Intervention
Ascites post Copper PPIUD insertionGastrointestinal disorders1/5283
Sudden death post Copper PPIUD insertionInjury, poisoning and procedural complications1/5283
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPPFP Intervention
Back pain post copper PPIUD insertionMusculoskeletal and connective tissue disorders3/5283
Infection post copper IUD insertionInfections and infestations2/5283
Vaginal infection post copper PPIUD insertionInfections and infestations2/5283
Vertigo post copper PPIUD insertionEar and labyrinth disorders2/5283
Insertion site infection post PP ImplantInfections and infestations4/10971
Urinary tract infection post copper PPIUD insertionRenal and urinary disorders1/5283
Influenza post copper PPIUD insertionInfections and infestations1/5283
Malaria post copper PPIUD insertionInfections and infestations1/5283
Gonorrhea post copper PPIUD insertionReproductive system and breast disorders1/5283
STI post copper PPIUD insertion (Gonorrhea/Chlamydia)Reproductive system and breast disorders1/5283

Baseline characteristics

Participants refer to women receiving services at study facilities during the intervention period. Enrollment is defined as inclusion in the analytic dataset under a waiver of informed consent. Clinic staff and promoters were not participants.

Age, Continuous
Age, Continuous(years)Cluster 1Cluster 2Cluster 3Cluster 4Pilot/Training FacilitiesTotal
Mean28.4 ± 6.528.1 ± 6.428.1 ± 6.328.1 ± 6.428.5 ± 6.228.3 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Cluster 1Cluster 2Cluster 3Cluster 4Pilot/Training FacilitiesTotal
Female69545855395824611899238220
Male000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cluster 1Cluster 2Cluster 3Cluster 4Pilot/Training FacilitiesTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American69545855395824611899238220
White000000
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Cluster 1Cluster 2Cluster 3Cluster 4Pilot/Training FacilitiesTotal
Rwanda69545855395824611899238220
07

Study locations

1 site
  • Project San Francisco, Kigali
    Kigali, Kigali, Rwanda
08

References and documents

Publications

  • Wall KM, Ingabire R, Mazzei A, Umuhoza C, Parker R, Tichacek A, Nizam A, Sales JM, Haddad LB, Corso P, Allen S, Nyombayire J, Karita E. Implementation and evaluation of a large-scale postpartum family planning program in Rwanda: study protocol for a clinic-randomized controlled trial. Trials. 2022 Apr 22;23(1):337. doi: 10.1186/s13063-022-06261-5. PubMed 35459259 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 14, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification

Supporting information: Study protocol

09

Registry details

Key details

Study ID
NCT05056545
Lead sponsor
Emory University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Kristin Wall (Assistant Professor, Emory University) — Principal investigator
First posted
Sep 24, 2021
Start date
Aug 1, 2022
Primary completion
Sep 30, 2024
Completion
Mar 2027 (estimated)
Results posted
Sep 23, 2026
Last update
Sep 23, 2026

Study contacts

Kristin Wall, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion